Dowty ME - Search Results

1

Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter Activity.

Huh Y, Plotka A, Wei H, Kaplan J, Raha N, Towner J, Purohit VS, Dowty ME, Wolk R, Vourvahis M, King-Ahmad A, Mathialagan S, West MA, Lazzaro S, Ryu S, Rodrigues AD. Huh Y, et al. Among authors: dowty me. Pharm Res. 2023 Nov;40(11):2639-2651. doi: 10.1007/s11095-023-03564-3. Epub 2023 Aug 10. Pharm Res. 2023. PMID: 37561322 Free PMC article.

2

Evaluation of the Impact of Ritlecitinib on Organic Cation Transporters Using Sumatriptan and Biomarkers as Probes.

Wang X, Purohit V, Dowty ME, Rodrigues D, Luo L, Mathialagan S, Carey W, Plotka A, Kalluru H, Melissa O, Kaplan J, Huh Y, Vourvahis M, Wolk RM. Wang X, et al. Among authors: dowty me. J Clin Pharmacol. 2023 Jul;63(7):784-797. doi: 10.1002/jcph.2215. Epub 2023 Apr 5. J Clin Pharmacol. 2023. PMID: 36807251

3

A phase 1 study to investigate the absorption, distribution, metabolism and excretion of brepocitinib in healthy males using a ¹⁴ C-microdose approach.

Qiu R, Sharma R, Wei H, Kirkovsky L, Zhou Y, Martin DDA, Banfield C, Dowty ME. Qiu R, et al. Among authors: dowty me. Br J Clin Pharmacol. 2023 Oct;89(10):3056-3066. doi: 10.1111/bcp.15786. Epub 2023 Jun 20. Br J Clin Pharmacol. 2023. PMID: 37183779 Free article. Clinical Trial.

4

Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model.

Saadeddin A, Purohit V, Huh Y, Wong M, Maulny A, Dowty ME, Sagawa K. Saadeddin A, et al. Among authors: dowty me. AAPS J. 2024 Jan 24;26(1):17. doi: 10.1208/s12248-024-00888-9. AAPS J. 2024. PMID: 38267790

5

Correction: Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model.

Saadeddin A, Purohit V, Huh Y, Wong M, Maulny A, Dowty ME, Sagawa K. Saadeddin A, et al. Among authors: dowty me. AAPS J. 2024 Feb 21;26(2):27. doi: 10.1208/s12248-024-00895-w. AAPS J. 2024. PMID: 38383803 No abstract available.

6

Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy Individuals.

Wang X, Dowty ME, Tripathy S, Le VH, Huh Y, Curto M, Winton JA, O'Gorman MT, Chan G, Malhotra BK. Wang X, et al. Among authors: dowty me. Eur J Drug Metab Pharmacokinet. 2024 May;49(3):367-381. doi: 10.1007/s13318-024-00893-5. Epub 2024 Mar 30. Eur J Drug Metab Pharmacokinet. 2024. PMID: 38554232 Free PMC article. Clinical Trial.

7

Meta-Analysis of Noncompartmental Pharmacokinetic Parameters to Evaluate the Impact of CYP2C19 and CYP2C9 Genetic Polymorphisms on Abrocitinib Exposure.

Fostvedt L, Liu J, Wang X, Li Y, Johnson J, Wood L, Dowty M, Malhotra B, Valdez H, Nicholas T, Xue W. Fostvedt L, et al. Clin Pharmacol Drug Dev. 2024 Oct;13(10):1098-1107. doi: 10.1002/cpdd.1465. Epub 2024 Aug 30. Clin Pharmacol Drug Dev. 2024. PMID: 39212958

8

Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective.

Reddy MB, Cabalu TD, de Zwart L, Ramsden D, Dowty ME, Taskar KS, Badée J, Bolleddula J, Boulu L, Fu Q, Kotsuma M, Leblanc AF, Lewis G, Liang G, Parrott N, Pilla Reddy V, Prakash C, Shah K, Umehara K, Mukherjee D, Rehmel J, Hariparsad N. Reddy MB, et al. Among authors: dowty me. Clin Pharmacol Ther. 2024 Oct 18. doi: 10.1002/cpt.3477. Online ahead of print. Clin Pharmacol Ther. 2024. PMID: 39422118 Review.

9

The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Ritlecitinib, a Janus Kinase 3 and Tyrosine-Protein Kinase Family Inhibitor, in Humans.

Bauman JN, Doran AC, Gualtieri GM, Hee B, Strelevitz T, Cerny MA, Banfield C, Plotka A, Wang X, Purohit VS, Dowty ME. Bauman JN, et al. Among authors: dowty me. Drug Metab Dispos. 2024 Sep 16;52(10):1124-1136. doi: 10.1124/dmd.124.001843. Drug Metab Dispos. 2024. PMID: 39111823

10

Integrating Clinical Variability into PBPK Models for Virtual Bioequivalence of Single and Multiple Doses of Tofacitinib Modified-Release Dosage Form.

Purohit V, Sagawa K, Hsu HJ, Kushner J, Dowty ME, Tse S, Lin J, Blanchard A, Mukherjee A, Le V, Chang C. Purohit V, et al. Among authors: dowty me. Clin Pharmacol Ther. 2024 Oct;116(4):996-1004. doi: 10.1002/cpt.3313. Epub 2024 May 26. Clin Pharmacol Ther. 2024. PMID: 38797995 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

56 results

Search Page

Filters